Multimodal MRI Neuroimaging Biomarkers for Cognitive Normal Adults, Amnestic Mild Cognitive Impairment, and Alzheimer's Disease by Lin, Ai-Ling et al.
Hindawi Publishing Corporation
Neurology Research International
Volume 2012, Article ID 907409, 17 pages
doi:10.1155/2012/907409
Review Article
Multimodal MRI NeuroimagingBiomarkers for Cognitive
NormalAdults, AmnesticMild Cognitive Impairment,and
Alzheimer’sDisease
Ai-LingLin,1 AngelaR. Laird,1 Peter T. Fox,1 andJia-Hong Gao2
1Research Imaging Institute, The University of Texas Health Science Center at San Antonio,
7703 Floyd Curl Drive, San Antonio, TX 78229, USA
2Departments of Radiology, Psychiatry, and Behavioral Neuroscience and Brain Research Imaging Center, The University of Chicago,
5841 South Maryland, MC 2026, Chicago, IL 60637, USA
Correspondence should be addressed to Ai-Ling Lin, lina3@uthscsa.edu and Jia-Hong Gao, jgao@uchicago.edu
Received 16 March 2011; Revised 11 May 2011; Accepted 8 June 2011
Academic Editor: Andrea Cherubini
Copyright © 2012 Ai-Ling Lin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Multimodal magnetic resonance imaging (MRI) techniques have been developed to noninvasively measure structural, metabolic,
hemodynamic and functional changes of the brain. These advantages have made MRI an important tool to investigate
neurodegenerative disorders, including diagnosis, disease progression monitoring, and treatment eﬃcacy evaluation. This paper
discusses recent ﬁndings of the multimodal MRI in the context of surrogate biomarkers for identifying the risk for AD in
normal cognitive (NC) adults, brain anatomical and functional alterations in amnestic mild cognitive impairment (aMCI), and
Alzheimer’s disease (AD) patients. Further developments of these techniques and the establishment of promising neuroimaging
biomarkers will enhance our ability to diagnose aMCI and AD in their early stages and improve the assessment of therapeutic
eﬃcacy in these diseases in future clinical trials.
1.Introduction
Aging is the greatest risk factor for neurodegenerative disor-
ders in general, but speciﬁcally for Alzheimer’s disease (AD).
With the increasing life expectancy in developed countries,
the incidence of AD, and consequently its socioeconomic
impact, is growing. AD currently aﬀects about 4.5 million
Americans, which costs the USA economy more than $100
billion each year. The number of AD patients is projected
to increase to 11–16 millions by 2050, with a cost exceeding
$380 billion per year [1, 2].
To identify AD and monitor disease progression, neu-
ropsychological tests such as the Mini-Mental State Exam
(MMSE) and the cognitive subscale of the Alzheimers
disease assessment (ADAS Cog) [3] are currently the most
commonly used strategies. However, these tests have several
limitations, as follows. MMSE is criticized by its marginal or
absent assessment of some cognitive abilities that are aﬀected
early in the course of Alzheimer’s disease or other dementing
disorders (e.g., limited memory and verbal ﬂuency items
and no problem solving or judgment items), and its relative
insensitivity to very mild cognitive decline, particularly in
highly educated individuals. ADAS Cog is limited by its rel-
atively poor test-retest reliability, which likely reﬂects the
inﬂuence of other factors on the patients’ performance (e.g.,
the patients’ mood). Furthermore, these tests are not able to
distinguish the risk for AD in preclinical groups (cognitively
normal elderly adults) or predict the conversion to AD from
preclinical and mild cognitive impairment (MCI) groups.
The National Institute of Aging (NIA) has recently
announced the revised clinical diagnostic criteria for AD
dementia for the ﬁrst time in 27 years (http://www.nih
.gov/news/health/apr2011/nia-19.htm). Instead of address-
ing the disease and describing only later stages when
symptoms of dementia are already evident, the updated
guidelines cover the full spectrum of the disease as it
gradually changes over many years. They describe (i) the
earliest preclinical stages of the disease, (ii) MCI, and2 Neurology Research International
(iii)dementiaduetoAlzheimer’spathology.Importantly,the
guidelines now address the use of imaging and biomarkers
in blood and spinal ﬂuid that may help determine whether
changes in the brain and those in body ﬂuids are due to AD.
In this paper, we will focus on the imaging biomarkers as
addressed in the new criteria. Speciﬁcally, we will discuss the
surrogatebiomarkersdevelopedbythemultimodalmagnetic
resonance imaging (MRI) methods for identifying the risk
for AD in normal cognitive (NC) adults; brain anatomical
and functional alterations in amnestic MCI (aMCI) and AD
patients.
2. Brief Overviewof MultimodalMRI
Neuroimaging Biomarkers
2.1. Structural Biomarkers. The high spatial resolution, sen-
sitivity, and speciﬁcity of MRI (e.g., resolution: 0.8mm iso-
tropic; sensitivity: 80–94%; speciﬁcity: 60–100%) have made
it a powerful tool to identify structural alterations and brain
atrophy using volumetric measurements of the entire brain
[4, 5]. With advanced computer software, the neocortex
of the brain on the MRI scans can be automatically
subdivided into 32 gyral-based region of interests (ROIs)
per hemisphere, including gray matter (GM), white matter
(WM), and hippocampus volumes [6–8].
GM loss can also be determined by measuring cortical
gray matter thickness (GMT). GMT is determined by cal-
culating the three-dimensional distance from the outer cor-
tical surface to the inner cortical GM-WM boundary using
cortical modeling from the high-resolution MRI structural
images (Figure 1). WM integrity can be assessed with diﬀu-
sion tensor imaging (DTI). In brain tissues, the microscopic
motion of water molecules is hindered by boundaries of
tissue structure. In highly structured tissue such as WM, this
motion is highly anisotropic and DTI provides directional
informationaboutit.LossinWMstructureresultsintheloss
in anisotropy, which can be easily detected by DTI [9, 10].
2.2. Functional Biomarkers. Functional-based MRI can de-
tect alterations and monitor disease progression related to
brain metabolism, hemodynamics, and connectivity. Func-
tional connectivity MRI (fcMRI) has been developed as a
technique to determine the resting state brain connectivity
as measured by the basal blood oxygenation-level-dependent
(BOLD) signal. In its simplest form, functionally connected
networks can be identiﬁed using a seed-based correlational
approach, in which the average resting state time series
from a region of interest is correlated with all other voxels
in the brain [2, 11–14]. In contrast to this correlational
method, independent component analysis (ICA) is a more
advanced multivariate analysis method that allows resting
state fMRI data to be decomposed into sets of independent,
intrinsic brain networks [15–17]. In either approach, each
functional network’s neuronal activity is associated with a
hemodynamic response, which consists of an increase in
cerebral blood ﬂow (CBF) and oxyhemoglobin and a rel-
ative decrease in deoxyhemoglobin. The changes in the ox-
yhemoglobin-deoxyhemoglobin ratio result in changes in
BOLD signal.
Neuronal activity is tightly coupled with CBF (as men-
tioned above); therefore, another approach to assess the
disease progression of AD is to measure CBF (in the units
of mL/100g/min). MR-based CBF measurements have been
developed to investigate hemodynamic alteration in AD,
including arterial spin labeling (ASL) [18] and dynamic con-
trast techniques [19]. Compared with the traditional CBF
measurements using single-photon emission computed
tomography (SPECT) with Tc-99m radioactive tracers [20,
21], the absence of ionizing radiation or injection and the
ability to obtain high quality anatomical images within the
same scanning session make MRI-based CBF techniques
attractive methods for the study of AD, especially when re-
peated scans are needed for monitoring disease progression
or assessing treatment eﬀect.
Changes in neuronal activity during the progression of
AD may be associated with the changes in brain metabolism.
Brain metabolism can be measured with MR spectroscopy
(MRS). Using proton (1H) MRS, numerous metabolites
related to brain functions can be determined, including N-
acetyl aspartate (NAA), myoinositol (MI), creatine, choline,
glutamate,glutamineandlactate.NAAispresentonlywithin
neural cell body, axons and dendrites, it is thus considered
to be a marker of neuronal viability and function [22]. MI,
on the other hand, has considerably higher concentration in
g l i a lc e l l sa n dt h u si so f t e nt a k e na sag l i a lm a r k e r[ 23].
3. Preclinical-CognitivelyNormal Adults
Beyond age, family history is the most signiﬁcant risk factor
for AD, with maternal transmission being signiﬁcantly more
frequent than paternal transmission [24]. Biomarkers for
AD-associated pathological changes, including metabolic
deﬁcits and amyloid beta (Aβ) load, have been observed in
cognitively normal individuals who have maternal history of
late-onset AD (FHm) [25, 26].
Structural MRI has been used to assess brain volume
changesforcognitivelyintactelderlyindividualswithFHm,a
paternal history of AD (FHp) and no parental history of AD
(FH-) [27–29]. Compared with FH individuals, cognitively
healthy subjects with a family history of late-onset AD
had signiﬁcantly decreased gray matter volume (GMV) in
the precuneus, middle frontal, and superior frontal gyri
(Figure 2;[ 27]). FHm subjects had even signiﬁcantly smaller
inferior frontal, middle frontal, precuneus, and lingual gyri
compared with FH and FHp individuals (Figures 2 and 3)
[27, 28].
Another chief known genetic factor for AD is ε4a l l e l e
apolipoprotein E gene (APOE ε4). Increasing age and
carrying APOE ε4 are well-established risk factors for AD.
Healthy older APOE ε4 carriers, particularly ε4h o m o z y -
gotes, have demonstrated brain structure changes related to
noncarriers. In a recent study with a longitudinal cohort
of 1186 healthy elderly persons (65–89 years), Crivello et
al. found that an annual rate of gray matter volume lossNeurology Research International 3
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Figure 1: T1-weighted image processing pipeline consists of (a) skull stripping; (b) spatial normalization, RF homogeneity correction, and
tissue segmentation; (c, d) extraction of GM and WM pial surfaces; (e, f) calculation of GMT.
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Figure 2:Theﬁrst2rowsdisplaymapsfromsubjectswithamaternalfamilyhistoryofAlzheimer’sdisease(FHm)ascomparedwithsubjects
withnofamilyhistory(FH-)(a)andsubjectswithapaternalfamilyhistory(FHp)(b).Row(c)showsgraymattervolume(GMV)reductions
in APOE ε4-negative FHm subjects compared with APOE ε4-negative FH subjects. Statistical parametric maps showing GMV reductions in
normal FHp subjects as compared with FH subjects are in row (d). Areas of GMV decrease are represented on purple-to-yellow, blue-to-
light blue, dark orange-to-yellow, and green-to-light green color-coded scales for the 4 contrasts, reﬂecting Z scores between 2 and 5 for the
upper contrast and between 2 and 4 for the lower 3 contrasts. Areas of gray matter volume decrease are displayed on a standardized spatially
normalized MRI (adapted with permission from [27]).4 Neurology Research International
135
(a)
0.04
0.03
0.02
0.01
0
−0.01
−0.02
−0.03
FH-
P
r
e
c
u
n
e
u
s
a
t
r
o
p
h
y
FHp FHm
(b)
FH-
0.04
0.02
0
−0.02
−0.04
−0.06
P
a
r
a
h
i
p
p
o
c
a
m
p
a
l
a
t
r
o
p
h
y
FHp FHm
(c)
Figure 3: Increased regional atrophy in maternal history of Alzheimer’s disease (FHm) group compared to subjects without family history
of late-onset Alzheimer’s disease (FH-) and paternal history of Alzheimer’s disease (FHp) groups (adapted with permission from [28]).
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Figure 4: (a) Age eﬀect on the longitudinal followup of GMV for the three APOE ε4 groups, illustrating the signiﬁcant interaction between
age and the APOE ε4. ε4 (–/–): noncarriers for the APOE ε4 allele, and ε4 (+/–): heterozygous for the APOE ε4a l l e l e ,ε4 (+/+): homozygous
for the APOE ε4 allele (adapted with permission from [30]). (b) Regression of the normalized volume of the prefrontal callosal subregion
on age in APOE ε4 carriers (red) and noncarriers (blue). Thick lines show linear regression lines and dotted lines 95% mean conﬁdence
intervals of the slope. Formulas denote regression lines. Normalization was done to total intracranial volume (adapted with permission from
[31]).Neurology Research International 5
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Figure 5: Statistical parametric maps of the brain used to assess
subjects’ performance on memory-activation tests in carriers of
the APOE ε4 allele and carriers of the APOE ε3 allele. The signal
intensity increased signiﬁcantly in the left inferior frontal region,
the right prefrontal cortex, the transverse temporal gyri bilaterally,
and the left posterior temporal and inferior parietal regions in both
groups. However, both the extent and the intensity of activation
were greater among the carriers of the APOE ε4 allele. The carriers
of the APOE ε4 allele also had signiﬁcant increases in the left
parahippocampal, the left dorsal prefrontal cortex, and in the
inferiorandsuperiorparietallobesandtheanteriorcingulategyrus.
Direct comparisons of the carriers of the APOE ε4 allele and the
carriers of the APOE ε3 allele (bottom panel, which shows the
diﬀerence between the carriers) further demonstrated the greater
extent and magnitude of activity in the left prefrontal region and
bilateral orbitofrontal, superior temporal, and inferior and superior
parietal regions in the carriers of the APOE ε4 allele (adapted with
permission from [32]).
was seen in ε4 homozygotes, whereas no age eﬀect was seen
in ε4 heterozygotes and in noncarriers (Figure 4(a))[ 30].
Similarly, ε4 homozygotes had a signiﬁcant larger rate of
hippocampal volume loss than heterozygotes or noncarriers.
In another anatomical study, Filippini et al. observed white
matter atrophy, including corpus callosum (CC) volume and
all subregions, in both APOE ε4 carriers and noncarriers.
However, the slope has been steeper in the APOE ε4 carriers
compared with the noncarriers particularly in the prefrontal
region (P = 0.02) (Figure 4(b))[ 31].
In addition to structural changes, APOE ε4 has also
shown great impact on brain function. Memory is the ﬁrst
cognitivedomaintobeaﬀectedbyAD[42],andimpairments
have been found in APOE ε4 carriers relative to noncarriers
[43, 44]. Using functional MRI (fMRI), Bookheimer et al.
observed that during a memory task in a group of healthy
subjects (aged 47–82), APOE ε4 carriers demonstrated
signiﬁcant increases in the left parahippocampal region, the
left dorsal prefrontal cortex, the inferior-superior parietal
lobes, and the anterior cingulate gyrus (Figure 5;[ 32]). In
addition, the extent and the intensity of activation for the
APOE ε4 carriers were greater in the left inferior frontal
region, the right prefrontal cortex, the transverse temporal
gyri bilaterally, the left posterior temporal, and inferior
parietal regions relative to the noncarriers (carriers of the
APOE ε3 allele). Direct comparisons of APOE ε4 carriers
and noncarriers further demonstrated the greater extent and
magnitude of activity in the left prefrontal, bilateral or-
bitofrontal, and superior temporal regions. In carriers of the
APOE ε4 allele, it has been demonstrated in inferior and
superior parietal regions.
In a younger group (mean age = 21–30), APOE ε4c a r -
riers demonstrated increased task-induced brain activation
in hippocampus relative to the noncarriers [45, 46]. Overac-
tivity of brain function has also been found in young APOE
ε4 carriers but disproportionately reduced with advancing
ageevenbeforetheonsetofmeasurablememoryimpairment
(Figure 6;[ 33]). In both age groups, a signiﬁcant interaction
h a sb e e nf o u n db e t w e e na g ea n dA P O Eε4 status in the hip-
pocampi, frontal pole, subcortical nuclei, middle temporal
gyri,andcerebellum.TheseresultshavesuggestedthatAPOE
genotype determines age-related changes in brain function,
and greater activation reﬂects greater cognitive “eﬀort” by
APOE ε4 carriers to obtain the same level of performance
as the noncarriers, and/or reﬂect neuronal mechanism to
compensateforprocesses,suchasreducedsynapticplasticity,
neuronal growth, or altered long-term potentiation in the
carriers.
APOE ε4 carriers have also shown disrupted resting state
brain activity in the absence of Aβ or decreased CSF in
cognitively normal elderly (mean age = 62) using functional
connectivity MRI method [11–13, 47]. Similarly, young
APOE ε4 carriers (mean age = 21–30), although had no
diﬀerence in cognition and GM volume compared to their
age-mated controls, showed increase in default mode net-
work (involving medial temporal, medial prefrontal, and ret-
rosplenial cortical areas) coactivation [46], suggesting that
the function of these areas subject to the disease process in
AD is modulated by APOE ε4 allele at very early stage.
Taken together, these results provide evidence that in-
ﬂuence of the genetic eﬀect (familial and APOE ε4a l l e l e )
onneurophysiologicalcharacteristicsandtheriskforADcan
be detected using MRI decades prior to any clinical or neu-
ropathological expression of neurodegenerative process.
4. Mild CognitiveImpairment
MCI is a transitional state between normal aging and
dementia. MCI is a diagnosis given to individuals who expe-
rience memory problems greater than normally expected6 Neurology Research International
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Figure 6:AGE by GENE interactions in the “novel versus familiar” contrastof the encoding task.(a) Regions showing signiﬁcant interaction
between AGE and GENE factors (P<0.05, corrected for multiple comparisons) with plots of percentage signal change in brain regions
showing group-related diﬀerences where ε4 (orange) deﬁnes ε4-carriers and NC (green) deﬁnes noncarriers. (b) ROIs for the left and right
hippocampi overlaid on a structural image (left) with associated plot of average hippocampal percentage signal change showing signiﬁcant
age-by-gene interaction (left hippocampus: P = 0.002, right hippocampus: P = 0.003) (adapted with permission from [33]).Neurology Research International 7
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Figure 7: Top. Signiﬁcant mode of atrophy (MO) results showing the contrast MCI > CON (controls; arrows). Middle. Signiﬁcant MO
results showing the contrast AD > MCI. Bottom. Signiﬁcant MO results showing the contrast AD > CON. (adapted with permission from
[34]).
with typical aging, but who do not show other symptoms
of dementia, such as impaired judgment or reasoning.
MCI has various clinical subtypes, including amnestic sin-
gledomain(aMCI-S),amnesticmultipledomain(aMCI-M),
nonamnestic single domain (naMCI-S), and nonamnestic
multiple domain (naMCI-M) [48]. Nonamnestic forms of
MCI (naMCI, i.e., naMCI-S and naMCI-M) have had
ﬁndings suggestive of vascular disease, whereas amnestic
forms of MCI (aMCI, i.e., aMCI-S and aMCI-M) have
appeared to have demographic, genetic, and MRI ﬁndings
suggestive of AD pathology [48, 49]. Although aMCI can
be deﬁned using neuropsychiatric criteria, brain imaging
studies have aimed to develop measures that are sensitive
enough to distinguish aMCI from normal aging with high
speciﬁcity [50]. Many other studies attempt to diﬀerentiate
between aMCI subjects who will convert to AD, over a
speciﬁc followup interval versus those who remain stable or
ever recover [51]. In this section, we elaborate the current
ﬁndings in these two areas.
4.1. Distinguishing aMCI from Normal Aging. Although age-
related regional volume loss is apparent and widespread in
nondemented individuals [5, 52], aMCI is associated with
a unique pattern of structural vulnerability reﬂected in dif-
ferential volume loss in speciﬁc regions. In a cross-sectional
study, aMCI patients were observed with a signiﬁcant WM
abnormality in the region of crossing ﬁbers in the centrum
semiovale in comparison to NC (Figure 7)[ 34]. In a ten-
consecutive-year longitudinal study, 18 participants (among
138)whoconvertedfromnormaltoMCIshowedaccelerated
changes (compared to normal controls) on whole brain
volume, ventricular CSF (vCSF), temporal gray matter, and
orbitofrontal and temporal association cortices, including
the hippocampus (P ≤ 0.04) (Figure 8)[ 35].
Similar ﬁndings of vCSF increases in aMCI patients
compared to normal controls have been reported by Vemuri
et al. [53]. In this study, Vemuri and colleagues further
demonstrated that changes in serial structural MRI diﬀered
by APOE ε4 status overall among aMCI, with higher brain
atrophy rates in APOE ε4 carriers. In addition, MR-based
structural biomarkers, compared with other biomarkers
(e.g., CSF), showed higher correlation with concurrent
change on general cognitive and functional indices in
impaired subjects.
Functional abnormality has also been shown in aMCI
patients. Compared with healthy controls, aMCI patients
had a regional pattern of brain disconnection between the
posterior cingulate cortex (PCC) and the medial prefrontal
cortex and the rest of the brain. These disconnections8 Neurology Research International
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Figure 8: Patterns of GMV loss in MCI and normal aging. Average
slopes of RAVENS maps for normal (a) and MCI (b) groups.
The red-yellow color indicates greater volume loss. Bottom row:
diﬀerence between the two groups; blue/green are regions in
which MCI subjects showed higher rate of gray matter decrease.
(c) Red/yellow colors reﬂect an increase of periventricular small
vessel disease, which appears gray in T1-weighted images and
is segmented as gray matter. The color bars display estimated
regression coeﬃcients and are deﬁned by the following numbers,
all inmm3/year (per voxel in the template space): a = −0.020,
b = −0.0053, c = 0.026, d = 0.0053, e = −0.0053, and f = −0.023
(adapted with permission from [35]).
could be observed even in the absence of GM atrophy
(Figure 9)[ 36].
4.2. Conversion from aMCI to AD. Cognitively normal eld-
erly subjects convert to AD at a rate of only 1-2% per year,
whereasaMCIsubjectsconverttoADatarateof12–15%per
year [54]. Studying the similarities and diﬀerences between
aMCI and AD would provide valuable information of the
disease mechanism and progression. Multimodal MRI oﬀers
noninvasivemethodsfordetectionandpossiblypredictionof
the conversion from aMCI to AD [6–8]. In a 3-year followup
of 118 aMCI individuals who progressed to a diagnosis
of AD, Desikan et al. reported that atrophy in the medial
temporal cortex (as measured by hippocampal volume,
entorhinal cortex thickness, amygdala volume, temporal
pole thickness, and parahippocampal gyrus thickness) can
accurately and reliably predict time to disease progression
[6, 7]. They demonstrated that aMCI individuals with
signiﬁcant atrophy of the medial temporal factor regions are
three times as likely to progress to AD, compared with aMCI
individuals with preserved medial temporal factor regions.
Their results also demonstrated that amygdala and temporal
pole may be additional important structures for predicting
the conversion from aMCI to AD. Similar observations were
foundinameta-analysisinvolving40studiesofimagingdata
from 1351 patients, suggesting that atrophy in the (trans)
entorhinal area and hippocampus most reliably predict the
progression from aMCI to AD [55]. These data provide
strong evidence that AD-related volume losses are most
readily detected in the medial temporal lobe in aMCI. The
r e d u c t i o ni nm e d i a lt e m p o r a ll o b ev o l u m ei st h e r e f o r ea n
important indicator in predicting the transition of aMCI to
AD.
MR-based ASL techniques provide a functional bio-
marker (perfusion) to predict the progression from MRI
to AD. In a longitudinal study (2.7 ± 1.0 years), Chao
et al. reported that the MCI individuals who converted to
dementia displayed hypoperfusion in the right precuneus,
right inferior parietal cortex, and right middle frontal cortex
[56]. A similar ﬁnding was reported in the Schroeter et
al. meta-analytic study (involving 1351 patients) in which
hypoperfusion in the inferior parietal lobules was found to
most reliably predict the progression from aMCI to AD [55].
Furthermore, baseline perfusion from the right precuneus
predicted subsequent declines in clinical dementia rating
sumofboxes,functionalactivatesquestionnaireandselective
attention (Stroop Switching), and baseline perfusion from
therightmiddlefrontalcortexpredictedsubsequentepisodic
memory decline. These results suggest that hypoperfusion as
detected by ASL MRI can predict progression from MCI to
AD.
5. Alzheimer’s Disease
AD is histopathologically characterized by the formation of
β-amyloid (Aβ) plaques and neuroﬁbrillary tangles (NFT).
Progressions of the Aβ plaques and NFT pathology of
AD correlate closely with loss of neurons and synapses
[57]. These losses further result in gross atrophy, including
cortical gray matter loss, reduced subcortical gray, and white
matter volumes, as well as expanding ventricular and sulcal
cerebrospinal ﬂuid (CSF) spaces [37, 38]( Figure 10; similar
regions of Aβ/NTF deposition and brain atrophy in AD). In
AD, this brain atrophy is localized to the medial temporal
limbic cortex during its earliest states. At later stages of
disease, it progresses to paralimbic cortical regions and the
neocortex [57]. The temporal limbic cortex has essential
roles in episodic memory. Since memory impairment is
the earliest symptom of AD, the temporal limbic cortex
(including entorhinal cortex and hippocampus) has been an
attractivetargetforstructuralneuroimaging studies[58–62].
Using brain volumetric measurements, patients with
mild AD showed signiﬁcantly smaller brain regions ofNeurology Research International 9
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Figure 9: Distribution of reduced regional GMV (top panel on the left) and functional connectivity (top panel on the right) observed in
patients with fully developed dementia (AD) compared with healthy subjects (HS). Changes of functional connectivity were assessed using
both posterior cingulate (PCC) and medial prefrontal cortex (mPFC) driven connectivity maps (adapted with permission from [36]).
hippocampus (25%) and entorhinal cortex (37%) than
healthy elderly controls [58–62]. In a number of longitudinal
studies, signiﬁcantly higher rates of brain atrophy were
observed in AD [63–66] .T h eg l o b a la t r o p h yr a t ei nn o r m a l
aging typically increases from 0.3% to 0.5% per year at age
70–80 but increases from 2% to 3% per year in AD [67–
69]. Similar regional observations have also been found in
hippocampus (controls, 1.0% to 1.7% per year; AD, 3.0% to
5.9% per year) and in entorhinal cortex (controls, 1.4% to
2.9% per year; AD, 7.15 to 8.4% per year) [2, 70, 71].
MR-based volume measures, particularly for the hip-
pocampus, have been shown to be a strong structural bi-
omarker for AD, as follows [72–74]. First, it has been
demonstrated that a signiﬁcant correlation exists between
MRI and histological-based hippocampal volumes (r = 0.97,
P<0.001); the diﬀerence in the hippocampal volumes
between normal and AD groups was 42% for the MRI data,
and 40% for the histology data after adjusting for tissue
shrinkage during specimen processing. Moreover, both the
histological and MRI hippocampal volume measurements10 Neurology Research International
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Figure 10: Gray matter deﬁcits spread through the limbic system in moderate AD. Average maps of gray matter density in patients and
controls were subtracted at their ﬁrst scan (A and B) and at their followup scan 1.5 years later (C and D). Colors show the average percentage
loss of gray matter relative to the control average. Profound loss engulfs the left medial wall (>15%; B and D). On the right, however,
the deﬁcits in temporoparietal and entorhinal territory (A) spread forward into the cingulate gyrus 1.5 years later (C). Limbic and frontal
zones clearly show diﬀerent degrees of impairment (C). MRI-based changes, in living patients, agree strongly with the spatial progression of
β-amyloid (Aβ) and NFT pathology observed after mortem (Braak Stages B, C, and III to VI), (adapted with permission from [37, 38]).
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Figure 11: Average gray matter loss rates in healthy aging and AD. The maps show the average local rates of loss for gray matter, in groups
of controls (top, (a)–(d)) and patients with AD (bottom, (e)–(h)). Loss rates are <1% per year in controls. They are signiﬁcantly higher in
AD and strongest in frontal and temporal regions (g, h) at this stage of AD. (adapted with permission from [39]).
were signiﬁcantly associated with the number of hippocam-
pal neurons (r = 0.91, P<0.001 and r = 0.90, P<0.01).
Second, when compared with a temporal lobe neocortical
reference volume, the hippocampal volume showed an an-
atomically unique correlation to memory performance such
as delayed verbal recall [72–74].
With GMT measurements, mild-to-moderate AD sub-
jects have cortices that are an average of 18% thinner relative
to healthy controls (AD = 3.1 ± 0.28mm, controls = 3.74 ±
0.32mm) [75]. Signiﬁcant GMT declines in AD were found
in temporal, orbitofrontal, and parietal regions. The most
pronounced changes occur in the allocortical region of the
medial temporal lobes, which outlines the parahippocampal
gyrus representing a loss of >1.25 millimeters of cortical
thickness[75,76].Inafollowupstudy1.5yearslater,patients
with AD lost signiﬁcant GM (P<0.05 for overall annual loss
of gray matter) (Figures 11(e)–11(h); [39]) at a signiﬁcantly
higher rate than controls (P<0.042), with a total gray
matter loss rate of 5.03 ± 2.28% per year (left hemisphere
5.43 ± 3.29% per year; right hemisphere 4.64 ± 3.31% per
year, whereas few regions in healthy controls exceeded a
1% annual gray matter loss). Regions with a prominent 4-
5% annual loss included the right cingulate, temporal, and
frontal cortices bilaterally (Figure 11, bottom row).
GMT changes are strong structural biomarkers for
AD. Highly signiﬁcant linkage was found relating greater
GMT deﬁcits to lower cognitive scores on the MMSE
(Figure 12;[ 39]). These correlations were observed in allNeurology Research International 11
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Figure 12: Mapping links between cognitive performance and changing brain structure. These maps show the signiﬁcance of the linkage
between gray matter reductions and cognition, as measured by MMSE score. Variations in temporal, parietal, and ultimately frontal (e)
tissuearelinkedwithcognitivestatus.Lessgraymatterisstronglycorrelatedwithworsecognitiveperformance,inallregionswithprominent
deﬁcits. Linkages are detected most strongly in the left hemisphere medial temporoparietal zones (d). As expected, no linkages are found
with sensorimotor gray matter variation (b), which was not in signiﬁcant deﬁcit in late AD (adapted with permission from [39]).
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Figure 13: First row: signiﬁcant FA results showing the contrast MCI > AD; second row: signiﬁcant FA results showing CON (controls) >
AD (adapted with permission from [34]).
brain regions, including the temporal, parietal, and limbic
cortices. Correlations were also found between frontal gray
matter reduction and lower MMSE scores, but only at the
later time point, when frontal gray matter was in signiﬁcant
deﬁcit (Figure 12(e)). No correlations were found between
gray matter diﬀerences in sensory and motor cortices and
cognitive performance (Figure 12(b), blue, S/M). These
results support the theory that the relationship between
brain structure and cognition is regionally speciﬁc in AD,
at least initially (Figure 12(b)). Correlations were observed
to be strongest in regions with greatest average loss, such
as the left cingulate and left temporal and parietal cortices
(Figure 12(d)).
WMdegenerationhasalsobeenconsideredanimportant
indicator of AD. In a comparison of healthy young versus
older adults, WM has been found to decline in volume
with increasing age but is further reduced in AD, with
parahippocampal, entorhinal, inferior parietal, and rostral12 Neurology Research International
0.46
0.44
0.42
0.4
0.38
0.36
0.34
0.32
0.3
M
e
a
n
F
A
−1.6 −1.2 −0.8 −0.4 0 0.4 0.8
Memoryc o m posite
r = 0.51 P = 0.003
Figure14:SigniﬁcantcorrelationsbetweenregionalalterationsofFAinpatientsandthecompositememoryscores(adaptedwithpermission
from [40]).
middle frontal areas showing the strongest AD-associated
reductions in WM [77]. AD patients, similar to aMCI
patients (but more severe), have shown signiﬁcant increase
in diﬀusion atrophy in the region of crossing ﬁbers in the
centrumsemiovale(Figure 6;[34]),Theyhavefurthershown
regionally speciﬁc shape abnormalities and reduction in
fractional anisotropy (FA) in the corpus callosum, anterior
commissure,uncinatefasciculus,cingulumtract,andsagittal
stratum tract (these have not observed in aMCI patients in
comparison to NC; Figure 13;[ 34, 78, 79]). These results
suggest that disruption in the white matter tracts near the
temporal lobe may represent the secondary consequence of
the medial temporal lobe pathology in AD. This is consistent
withtheobservationthatFAvaluesaresigniﬁcantlyrelatedto
memory performance among AD patients (Figure 14;[ 40]).
Structural imaging is able to detect AD only at a stage
in which the disease has progressed so far that neurons are
already irreversibly lost. Ideally, AD should be diagnosed at
an earlier stage in which neurons are impaired by the disease
process, but not yet fully damaged, and thus can be poten-
tially salvaged [2, 13]. In contrast, alterations of neuronal
activity, metabolism, and hemodynamics are accompanied
by the impairment of neurons and usually precede neuronal
death prior to any cognitive deﬁcits. Functional MRI has
shown great promise in the detection of AD at this very early
stage of disease, as well as during disease progression.
Disrupted functional connectivity has been observed in
patients with AD in the default mode network, which is
associated with autobiographical memory retrieval [80, 81].
Similar to aMCI, functional connectivity abnormalities were
observed in the PCC and a set of default mode regions,
including the medial prefrontal cortex, hippocampus, infe-
rior temporal cortex, bilateral visual cortices, and the pre-
cuneus in AD patients [82]. This disruption of connectivity
was observed to intensify during aMCI and AD disease
progression (Figure 15;[ 41]). With concurrent fcMRI and
structural MRI measurements, the PCC showed reduced
connectivity in patients progressing into AD even in the
a b s e n c eo fG Ma t r o p h y( Figure 9;[ 36]). This indicates that
functional connectivity abnormalities precede GM atrophy
in the PCC and supports the hypothesis that GM atrophy in
speciﬁc regions of AD brains likely reﬂects a long-term eﬀect
of brain disconnection.
In AD patients, signiﬁcant declines of CBF have been
found in frontal, parietal, and temporal regions (P<
0.001), with more marked reductions in those patients with
severe dementia. Covariance analysis revealed that aging
and disease severity have a pronounced eﬀect on CBF,
especiallythatoftheleftparietalregion.Signiﬁcantdecreases
of CBF have been detected with ASL-MRI in temporal,
parietal, and frontal cortex and the posterior cingulate in
patients with AD, compared to the healthy elderly controls.
The observations have been consistent with those observed
using SPECT. Using dynamic contrast method, CBF has
been found signiﬁcantly reduced in insular cortex [83, 84].
Because the insula is an important brain structure for theNeurology Research International 13
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Figure 15: (a–d) Left to right: sagittal, coronal, and axial views of T1-weighted MNI canonical brain templates show intragroup maps of the
default mode network (DMN) based on the seed of the PCC in, (a), control group, (b), mild AD group, (c), moderate AD group, and (d),
severe AD group. The regions involved in the DMN are labeled as follows in (a): a = ventral MPFC, b = PCC, c = precuneus and/or cuneus,
d = ITC, e = thalamus, and f = inferior parietal cortex. Color scale = t values (adapted with permission from [41]).
autonomic control of blood pressure and heart rate, the
observations suggested that AD pathology has eﬀect on
ventral autonomic cardioregulatory dysfunction.
In AD patients, signiﬁcant N-acetyl aspartate (NAA)
reductions have been found in various brain areas, including
PCC, hippocampus, and GM of the temporal, parietal, and
sometimes the frontal as well as occipital cortices [23, 85].
Decrease in NAA reﬂects a combination of losses of neu-
ronal cells/dendritic structures, reduced myelination, and
decreased neuronal metabolism. As a result, the degree of
cognitive impairment has been well correlated with the de-
gree of NAA decrease; poor performance on memory tests
correlated with lower gray matter NAA level [86]. In contrast
to NAA, myoinositol (MI), a glial biomarker, has been found
tobedramaticallyincreasedinAD.ElevatedMIismostlikely
due to the increase of gliosis in AD. Taken together, NAA
and MI are important and useful metabolic biomarkers to
distinguish AD from normal aging.14 Neurology Research International
6. FutureDirections
Mitochondrial dysfunction is a well-known biomarker of
AD. Mitochondria are the predominate source (>98%) of
energy production in mammals, yielding ATP through ox-
idative phosphorylation of glucose. In the brain, oxidative
metabolism (O2 consumption) is the predominant source
of energy (ATP generation), supporting baseline demands
and maintaining viability, as well as responding rapidly and
in a highly regional manner to changes in neuronal activity
induced by task performance. Failure to maintain adequate
levels of tissue oxygenation rapidly results in tissue death as
observed of brain atrophy in AD patients.
To identify the integrity of the mitochondrial function,
cerebral metabolic rate of glucose (CMRGlc) and oxygen
(CMRO2) are the most-well known indicators [87]. CMRGlc
measurements in AD research have been well established
with positron emission tomography (PET) methods. For
instance, signiﬁcant decreases of glucose metabolism have
been found in young APOE ε4 carriers (30 years old) in
brain areas associated with AD pathology [88]. In contrast,
CMRO2 measurements are not feasible using PET methods,
especially for AD patients, due to the diﬃculties of obtaining
arterial blood samples. In addition, the radioactive nature of
PET allows less repetitive scans, which limits the monitoring
of the disease progress. Therefore, considerable eﬀorts have
been made to develop MRI-based, noninvasive, CMRO2
measurements. Baseline CMRO2 and task-induced changes
in CMRO2 determinations have been proposed by sev-
eral methods, including T2-relaxation-under-spin-tagging
(TRUST) and quantitative BOLD (qBOLD) techniques
[89–93]. These MR-based metabolic imaging methods, in
addition to MRS, are expected to be very useful as diagnostic
and prognostic biomarkers in AD. However, future studies
allowing for rigorous assessment of test-retest reliability and
power calculation compared to the established imaging tech-
niques are necessary before these CMRO2 methods can be
accepted as other complementary and/or established func-
tional neuroimaging biomarkers for AD.
The development and validation of structural and func-
tionalbiomarkerswillenableMRItobeutilizedasapowerful
tool for evaluation of therapeutic eﬃcacy in AD in large-
scale clinical trials. For example, Jack et al. estimated that in
each arm of a therapeutic trail with conventional volumetric
measures for hippocampal volume, only 21 subjects would
be required to detect 50% reduction in the rate of decline.
This compares 241 subjects if MMSE scores were used; 320
subjects if ADAS Cog scores were used [54]. Combining with
other biomarkers (e.g., CMRGlc by PET and Aβ/NFT CSF),
surrogatemarkersforADprogresscanbeidentiﬁedandused
forclinical/cognitivetestsinclinicaltrials.Nonetheless,these
surrogatemarkersmustbevalidatedtobereproducibleinthe
treatment setting, across various types of treatments, across
imaging centers, and across time. A multicenter AD research
project, known as the Alzheimer’s Disease Neuroimaging
Initiative (ANDI) (http://adni.loni.ucla.edu/), was launched
in 2004 to meet this goal.
7. Conclusions
The incidence of Alzheimer’s disease is increasing with the
extended lifespan in developed countries. The development
of neuroimaging biomarkers is a pressing need to detect the
early risk of AD (from NC), predict and monitor disease
progression (from aMCI). Multimodal MRI methods have
been developed to meet this demand by providing useful and
important structural and functional biomarkers in AD. The
validation of the surrogate biomarkers will have profound
implications in AD clinical trials, including the prevention
and deceleration of AD onset, as well as the evaluation of
treatment eﬃcacy.
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